The histone deacetylase HDAC1 activates HIF1α/VEGFA signal pathway in colorectal cancer

Cheng Chen,Meng Wei,Chao Wang,Danping Sun,Peng Liu,Xin Zhong,Qingsi He,Wenbin Yu
DOI: https://doi.org/10.1016/j.gene.2020.144851
IF: 3.913
2020-09-01
Gene
Abstract:<p>Tumor angiogenesis is a common feature of rapidly growing solid tumors, accelerated by tumor hypoxia. It is associated with subsequent metastasis, progression, poor prognosis, and aggressive phenotype in many types of cancer. The hypoxia-inducible factors/vascular endothelial growth factor 1(HIF1/VEGF) signal pathway plays an important role in tumor angiogenesis. Proteasome-mediated ubiquitin degradation pathway is one of the most important processes involved in regulating the level of cellular HIF-1α. Our study revealed that Histone Deacetylase 1 (HDAC1) directly inhibits the ubiquitination of HIF1α. Additionally, HDAC1 activates HIF1α/VEGFA signaling pathway, promoting s tumor angiogenesis. These findings have enhanced our understanding of the molecular mechanisms of colorectal (CRC) tumor angiogenesis. HDAC1/HIF1α/VEGFA signaling pathway may provide a novel therapeutic window for CRC.</p>
genetics & heredity
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the role and mechanism of histone deacetylase 1 (HDAC1) in colorectal cancer (CRC), especially how HDAC1 promotes tumorigenesis and development by activating the hypoxia - inducible factor 1α/vascular endothelial growth factor A (HIF1α/VEGFA) signaling pathway. The study reveals that HDAC1 is over - expressed in CRC, and this over - expression is related to the enhanced proliferation, migration and invasion abilities of the tumor. In addition, the study also finds that HDAC1 can directly interact with HIF1α, inhibit its ubiquitination, thereby stabilizing the HIF1α protein, further activating the HIF1α/VEGFA signaling pathway and promoting tumor angiogenesis. These findings not only enhance the understanding of the pathogenesis of CRC, but also provide new potential targets for the treatment of CRC.